The EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) provide recommendations for the diagnosis, treatment, and follow-up of NAFLD patients. The guidelines are a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference. NAFLD is characterized by excessive hepatic fat accumulation associated with insulin resistance (IR) and is defined by steatosis in >5% of hepatocytes. It includes two distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The diagnosis of NAFLD requires exclusion of secondary causes and daily alcohol consumption ≥30 g for men and 20 g for women. The guidelines recommend screening for NAFLD in at-risk populations, with a focus on practical use and advancing research. They emphasize the importance of lifestyle changes, including diet and physical activity, for managing NAFLD. For patients with advanced fibrosis or cirrhosis, bariatric surgery and liver transplantation are considered options. The guidelines also address the role of pharmacotherapy, with specific recommendations for metformin, pioglitazone, vitamin E, and other agents. They highlight the importance of monitoring cardiovascular complications and other extrahepatic disorders associated with NAFLD. Overall, the guidelines aim to improve patient care, raise awareness, and assist stakeholders in decision-making by providing evidence-based data.The EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) provide recommendations for the diagnosis, treatment, and follow-up of NAFLD patients. The guidelines are a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference. NAFLD is characterized by excessive hepatic fat accumulation associated with insulin resistance (IR) and is defined by steatosis in >5% of hepatocytes. It includes two distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The diagnosis of NAFLD requires exclusion of secondary causes and daily alcohol consumption ≥30 g for men and 20 g for women. The guidelines recommend screening for NAFLD in at-risk populations, with a focus on practical use and advancing research. They emphasize the importance of lifestyle changes, including diet and physical activity, for managing NAFLD. For patients with advanced fibrosis or cirrhosis, bariatric surgery and liver transplantation are considered options. The guidelines also address the role of pharmacotherapy, with specific recommendations for metformin, pioglitazone, vitamin E, and other agents. They highlight the importance of monitoring cardiovascular complications and other extrahepatic disorders associated with NAFLD. Overall, the guidelines aim to improve patient care, raise awareness, and assist stakeholders in decision-making by providing evidence-based data.